To evaluate whether the risk of progression from psoriasis to psoriatic arthritis (PsA) is affected by the class of bDMARD used for treatment of psoriasis, in a real-world cohort with a large follow-up.

EULAR recommends early proteinuria reduction targets in lupus nephritis (LN) (≥25% at 3 months and ≥50% at 6 months). We examined the predictive value of these targets for achieving complete renal response (CRR) at 12 months, a surrogate for favorable long-term outcomes.

Women with systemic lupus erythematosus (SLE) are at increased risk of infertility due to disease activity and exposure to gonadotoxic therapies. Anti‑CD19 chimeric antigen receptor (CAR) T‑cell therapy has recently been shown to induce durable, drug‑free remission in refractory SLE; however, its effects on ovarian function remain unknown. We assessed longitudinal changes in reproductive endocrine markers to evaluate the impact of CAR T‑cell therapy on ovarian reserve and hypothalamic-pituitary-ovarian (HPO) axis function.

Salivary gland ultrasonography is a promising non-invasive modality for the evaluation of Sjögren's disease (SjD), but its diagnostic utility is limited by operator dependency. This study aimed to evaluate the classification performance of radiomics-based machine learning using parotid gland ultrasonography and to compare it with conventional visual assessment.

To map how sleep has been assessed in osteoarthritis (OA) and/or inflammatory arthritis (IA), and to synthesise the evidence on the prevalence, characteristics, and relationships between sleep disturbances and these conditions.

General practitioner (GP) delay is the main cause of referral delay for rheumatoid arthritis in the Netherlands due to insufficient experience with joint examination. This delay led to the launch of the early arthritis recognition clinic, in which rheumatologists screen patients for clinical arthritis using joint examination. Because the long-term effectiveness of this intervention is unknown, we measured functional disability and sustained disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis to establish its effectiveness.

To evaluate the efficacy and safety of anifrolumab (ANI) for the hematologic manifestations of systemic lupus erythematosus (SLE) in routine clinical practice.

Relapse is common in IgG4-related disease (IgG4-RD). While previous studies focus on treatments for active IgG4-RD, data on the management of relapsing IgG4-RD remains limited. We aimed to investigate the treatment strategies for relapsing IgG4-RD.

To evaluate longitudinal antiphospholipid antibody (aPL) patterns in newly diagnosed systemic lupus erythematosus (SLE) and their association with vascular events, disease activity and organ damage.

Real-world comparisons of rituximab biosimilars with originator rituximab have largely focused on oncology, with limited evidence in rheumatoid arthritis (RA). This gap is particularly pertinent to the Veterans Health Administration (VHA), where patients with RA are older and have greater comorbidity. We evaluated the effectiveness and safety of rituximab-pvvr versus originator rituximab in Veterans with RA by (1) describing treatment patterns, (2) assessing effectiveness, (3) evaluating adverse events, and (4) identifying reasons for switching back to the originator after initiating the biosimilar.

To compare kidney survival, mortality, and composite outcomes in lupus nephritis (LN) according to age at systemic lupus erythematosus (SLE) onset (late-onset ≥50 years vs early-onset 18-49 years) in a Latin American cohort.

Immune mediated inflammatory diseases (IMID) affect women of childbearing age, yet there is a lack of evidence about the risk of adverse pregnancy outcomes and the interaction with medication. This study aims to characterise prescribing patterns and pregnancy outcomes in women with an IMID diagnosis.

Cardiovascular disease (CVD) accounts for approximately 40% of deaths among patients with rheumatoid arthritis (RA), yet the burden of heart failure (HF) within this population remains poorly characterized. Using the KURAMA cohort, we aimed to quantify the prevalence of HF among RA outpatients and develop a practical HF screening tool that uses variables readily available to rheumatologists in routine clinical practice.

The role of C-reactive protein (CRP) in Psoriatic Arthritis (PsA) as a diagnostic and prognostic marker is debated. We compared clinical and epidemiological features, as well as long-term outcomes, between patients with "elevated" (>0.5 mg/dL) and patients with "normal" (≤0.5 mg/dL) CRP at diagnosis.

Juvenile idiopathic arthritis (JIA) is the commonest group of childhood arthritides. Despite the availability of advanced therapeutics, many children and young people (CYP) with JIA experience disease flares, and in some, chronic joint damage. Tailoring treatment based on unique biological profiles would benefit CYP with JIA given their variable clinical presentation and disease course. To date, biomarkers to predict treatment response are lacking. With advances in single cell technologies, we are now able to profile the genes and proteins of target tissues at unprecedented resolution to define the biological basis of disease and guide novel treatment approaches. The complex analyses and combination of biological and clinical outcome data from large datasets across disease phenotypes have become possible with the development of computational and machine learning methods. Here, we summarise the strategies to integrate data through enable multimodal based approaches to maximise precision medicine and research priorities for CYP with JIA.

To provide the first population-based estimates of pregnancy complications, adverse birth outcomes, and venous thromboembolism (VTE) among clinically selected women undergoing antiphospholipid antibody (aPL) testing, and to examine how risks vary by aPL status.

To assess how resolution of monosodium urate (MSU) depositions occurs in people with gout during urate-lowering therapy (ULT) by assessing both density reduction of 1) complete and 2) core part of MSU depositions. Furthermore, to evaluate potential changes in effective atomic numbers as a sign of tophi calcifications.